ATE362360T1 - Hemmer des phosphattransports - Google Patents

Hemmer des phosphattransports

Info

Publication number
ATE362360T1
ATE362360T1 AT02806234T AT02806234T ATE362360T1 AT E362360 T1 ATE362360 T1 AT E362360T1 AT 02806234 T AT02806234 T AT 02806234T AT 02806234 T AT02806234 T AT 02806234T AT E362360 T1 ATE362360 T1 AT E362360T1
Authority
AT
Austria
Prior art keywords
phosphate transport
transport inhibitors
lower alkyl
substituted
alkyl group
Prior art date
Application number
AT02806234T
Other languages
English (en)
Inventor
Thomas Jozefiak
Cecilia Bastos
Andrew Papoulis
Stephen Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE362360T1 publication Critical patent/ATE362360T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02806234T 2001-12-26 2002-12-24 Hemmer des phosphattransports ATE362360T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34466001P 2001-12-26 2001-12-26
US37164902P 2002-04-10 2002-04-10

Publications (1)

Publication Number Publication Date
ATE362360T1 true ATE362360T1 (de) 2007-06-15

Family

ID=26994039

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06077276T ATE464905T1 (de) 2001-12-26 2002-12-24 Phosphattransporthemmer
AT02806234T ATE362360T1 (de) 2001-12-26 2002-12-24 Hemmer des phosphattransports

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06077276T ATE464905T1 (de) 2001-12-26 2002-12-24 Phosphattransporthemmer

Country Status (7)

Country Link
US (2) US7119120B2 (de)
EP (2) EP1465638B1 (de)
JP (2) JP4610900B2 (de)
AT (2) ATE464905T1 (de)
AU (1) AU2002367396A1 (de)
DE (2) DE60220188T2 (de)
WO (1) WO2003057225A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
EP1537075B1 (de) * 2002-09-05 2009-07-01 Neurosearch A/S Diarylharnstoffderivate und deren verwendung als chloridkanalblocker
EP1398029A1 (de) * 2002-09-10 2004-03-17 LION Bioscience AG 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
US7491718B2 (en) * 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
AU2003282867A1 (en) 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
DE10257357A1 (de) * 2002-12-09 2004-06-24 Bayer Ag Fluorhaltige Benzaldehyde
AU2005250336B2 (en) * 2004-04-20 2011-06-09 Amgen, Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
US20060134225A1 (en) * 2004-10-15 2006-06-22 Moerck Rudi E Phosphate binder with reduced pill burden
TW200637539A (en) * 2005-01-20 2006-11-01 Shionogi & Co CTGF inhibitors
WO2007022466A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Hyperphosphatemia in domestic animals: compositions and methods of treatment
EP1928349A4 (de) * 2005-08-17 2008-10-01 Altairnano Inc Behandlung von chronischer niereninsuffizienz und anderer erkrankungen bei haustieren: zusammensetzungen und verfahren
DE102005044156A1 (de) * 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate
GB0526255D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP2009542653A (ja) * 2006-07-05 2009-12-03 ジェンザイム コーポレーション リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤
US8119693B2 (en) * 2007-05-08 2012-02-21 Sanford-Burnham Medical Research Institute Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
EP2307019A1 (de) * 2008-06-03 2011-04-13 Fresenius Medical Care Deutschland GmbH Pharmazeutische zusammensetzungen mit gammasekretasemodulatoren
HUE043090T2 (hu) * 2008-06-09 2019-08-28 Univ Muenchen Ludwig Maximilians Gyógyszerek fehérjék aggregálódásának gátlására olyan betegségeknél, amelyek fehérje-aggregálódással és/vagy neurodegeneratív megbetegedésekkel függnek össze
WO2010005922A1 (en) * 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ES2633689T3 (es) 2009-01-26 2017-09-22 Opko Ireland Global Holdings, Limited Regulación de fosfato con moléculas pequeñas
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
CN102918050B (zh) * 2010-03-05 2015-07-01 多普斯公司 肠顶端膜钠/磷协同转运的芳基氟磷酸酯抑制剂
KR101940207B1 (ko) 2010-05-12 2019-01-18 스펙트럼 파마슈티컬즈 인크 란탄 카보네이트 하이드록사이드, 란탄 옥시카보네이트 및 이들의 제조 및 사용 방법
JP5827328B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2590656B1 (de) 2010-07-07 2017-11-15 Ardelyx, Inc. Verbindungen und verfahren zur hemmung eines phosphattransports
EP2590965B1 (de) * 2010-07-07 2016-04-20 Ardelyx, Inc. Verbindungen und verfahren zur hemmung eines phosphattransports
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
ES2735992T3 (es) 2013-04-12 2019-12-23 Ardelyx Inc Compuestos de unión a NHE3 y procedimientos para inhibir el transporte de fosfatos
CN103467452B (zh) * 2013-09-11 2015-11-18 陕西理工学院 一种苯甲酰胺类化合物及其应用
CN106008360B (zh) * 2016-08-11 2018-10-16 华南农业大学 一种对氨基苯磺酰咪唑及其制备方法
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
JP7120549B2 (ja) * 2016-12-15 2022-08-17 小野薬品工業株式会社 Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
US12016834B2 (en) 2017-08-03 2024-06-25 Georgetown University Small molecule inhibitors of SLC25A1
EP3740482A1 (de) 2018-01-17 2020-11-25 Migal Galilee Research Institute Ltd. Neue inhibitoren des methionin-stoffwechselweges
CN111630032B (zh) * 2018-01-17 2024-06-07 米加尔-加利里研究院有限公司 新型蛋氨酸代谢途径抑制剂
WO2019179436A1 (zh) * 2018-03-20 2019-09-26 成都海创药业有限公司 一种酰胺类化合物及其在治疗癌症中的用途
EP3802514B1 (de) 2018-06-01 2022-08-03 Promega Corporation Inhibitoren von aus oplophorus-luciferase abgeleiteten biolumineszenz-komplexen
JP2022526827A (ja) 2019-04-11 2022-05-26 アンジオン バイオメディカ コーポレーション （ｅ）－３－［２－（２－チエニル）ビニル］－１ｈ－ピラゾールの固体形態
WO2021041561A2 (en) * 2019-08-26 2021-03-04 Avantaggiati Mauria Laura Treating non-alcoholic fatty liver disease and inflammatory steatohepatitis with slc25a1 inhibitors
US20250302833A1 (en) * 2022-05-11 2025-10-02 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treating or preventing cystic disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652868B1 (de) * 1992-07-28 2004-11-10 Aventis Pharma Limited Inhibitoren von c-amp phosphodiesterase
EP0619116A3 (en) * 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
ATE180468T1 (de) 1993-12-27 1999-06-15 Eisai Co Ltd Anthranilsäure derivate
HUP9802319A3 (en) * 1995-10-23 1999-12-28 Zymogenetics Inc Seattle Pharmaceutical compositions for treatment of bone deficit conditions
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO1999007382A1 (en) * 1997-08-06 1999-02-18 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
JP3972163B2 (ja) * 1999-06-18 2007-09-05 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
CO5190714A1 (es) 1999-07-20 2002-08-29 Smithkline Beecham Corp Inhibidores del transporte de fosfato
WO2001082924A1 (en) 2000-05-02 2001-11-08 Smithkline Beecham Corporation Phosphate transport inhibitors
PL359931A1 (en) 2000-05-12 2004-09-06 Smithkline Beecham Corporation Phosphate transport inhibitors
WO2002028353A2 (en) * 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors

Also Published As

Publication number Publication date
AU2002367396A1 (en) 2003-07-24
JP2010132674A (ja) 2010-06-17
DE60220188T2 (de) 2008-01-24
EP1465638A2 (de) 2004-10-13
JP4610900B2 (ja) 2011-01-12
US7119120B2 (en) 2006-10-10
DE60220188D1 (de) 2007-06-28
US20070021509A1 (en) 2007-01-25
WO2003057225A3 (en) 2004-04-08
US20040019113A1 (en) 2004-01-29
ATE464905T1 (de) 2010-05-15
EP1815860B1 (de) 2010-04-21
EP1815860A2 (de) 2007-08-08
EP1815860A3 (de) 2007-11-21
JP2005514413A (ja) 2005-05-19
DE60236117D1 (de) 2010-06-02
WO2003057225A2 (en) 2003-07-17
EP1465638B1 (de) 2007-05-16

Similar Documents

Publication Publication Date Title
ATE362360T1 (de) Hemmer des phosphattransports
DK0931788T3 (da) Metalloproteasehæmmere
DE69221794D1 (de) 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
NO20034595D0 (no) Kinolin- og kinazolinderivater med azolylgruppe
EA200101133A1 (ru) Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
ATE172452T1 (de) Bicyclische stichstoff enthaltende derivate als prolyl-endopeptidase inhibitoren
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
DE60111228D1 (de) Heteropolycyclische inhibitoren
MY101917A (en) Biocidal mixture
DK0806413T3 (da) 2-substituerede viatmin D3-derivater
DK0668279T3 (da) 6-azaindol thromboxansytaseinhibitor
ES2191763T3 (es) Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico.
DE69941307D1 (de) Prenyl transferasinhibitoren
EA200001036A1 (ru) Способы ингибирования mrp1
ATE413174T1 (de) Nicht-nucleoside revers-transcriptase inhibitoren
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
ATE430476T1 (de) Schlammbehandlung
EA199800931A1 (ru) Способ получения ингибиторов фосфодиэстеразы iv
MXPA03005556A (es) Derivados de 1,1-dioxo-1,2-benzotiacina-3-carboxamidas, metodo para prepararlos y composiciones farmaceuticas que los contienen.
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
DE60108873D1 (de) Nicht-antibakterielle tetrazykline als anti-pilz medikamente

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties